{
    "ticker": "BFRI",
    "name": "Biofrontera AG",
    "description": "Biofrontera AG is a biopharmaceutical company focused on the development and commercialization of innovative dermatological therapies. Founded in 2000 and headquartered in Leverkusen, Germany, Biofrontera operates with a mission to improve the quality of life for patients suffering from skin diseases, particularly skin cancer and other dermatological conditions. The company is best known for its flagship product, Ameluz\u00ae, a topical treatment for actinic keratosis, which is a precancerous skin condition. Biofrontera has also developed a proprietary photodynamic therapy (PDT) device, the BF-RhodoLED\u00ae, which is used in conjunction with Ameluz\u00ae to enhance treatment efficacy. In addition to its core dermatology portfolio, Biofrontera is engaged in ongoing research and development to expand its product offerings and address additional skin-related health issues. The company has a strong focus on international markets, particularly in the United States and Europe, and is committed to advancing dermatological care through innovative solutions. Biofrontera aims to establish itself as a leader in the dermatological industry by leveraging its expertise in photodynamic therapy and patient-centered care.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "Leverkusen, Germany",
    "founded": "2000",
    "website": "https://www.biofrontera.com",
    "ceo": "Dr. Hermann L\u00fcbbert",
    "social_media": {
        "twitter": "https://twitter.com/Biofrontera",
        "linkedin": "https://www.linkedin.com/company/biofrontera-ag"
    },
    "investor_relations": "https://www.biofrontera.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. Hermann L\u00fcbbert",
            "position": "CEO"
        },
        {
            "name": "Dr. Michael A. T. M. K. Lichtenberg",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Dermatological Products",
            "products": [
                "Ameluz\u00ae",
                "BF-RhodoLED\u00ae"
            ]
        }
    ],
    "seo": {
        "meta_title": "Biofrontera AG | Innovative Dermatological Solutions",
        "meta_description": "Explore Biofrontera AG, a leader in biopharmaceuticals focused on innovative dermatological therapies like Ameluz\u00ae for skin cancer treatment.",
        "keywords": [
            "Biofrontera",
            "Dermatology",
            "Biopharmaceuticals",
            "Actinic Keratosis",
            "Ameluz",
            "Photodynamic Therapy"
        ]
    },
    "faq": [
        {
            "question": "What is Biofrontera known for?",
            "answer": "Biofrontera is known for its innovative dermatological therapies, particularly Ameluz\u00ae for treating actinic keratosis."
        },
        {
            "question": "Who is the CEO of Biofrontera?",
            "answer": "Dr. Hermann L\u00fcbbert is the CEO of Biofrontera AG."
        },
        {
            "question": "Where is Biofrontera headquartered?",
            "answer": "Biofrontera is headquartered in Leverkusen, Germany."
        },
        {
            "question": "What are Biofrontera's main products?",
            "answer": "Biofrontera's main products include Ameluz\u00ae and the BF-RhodoLED\u00ae device."
        },
        {
            "question": "When was Biofrontera founded?",
            "answer": "Biofrontera was founded in 2000."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "GSK",
        "ABBV"
    ]
}